First, RA patients achieving a good response with an anti-TNF-α treatment display lower levels of IL-33 in serum and SF and IL-33R on immune cells compared to patients treated with methotrexate or non-responders to TNF-α inhibitors [28, 29]. This evidence concerns the gene TNF and rheumatoid arthritis.